The University of British Columbia

Cava Healthcare Inc.

Bioasis Technologies, Inc.

Tapimmune Inc.

Alternative Extracts Inc.

Biommune Technologies Inc.

Rayshad Gopaul

Robyn P. Seipp

Alvernia Francesca Setiadi

Jennifer Hartikainen

Wilfred A. Jefferies

Muriel D. David

Wilfred A Jefferies

Reinhard Gabathuler

Timothy Z Vitalis

Raymond John Andersen

David Williams

Susan Shu-Ping Chen

Kyung Bok Choi

Lilian Nohara

Patrick L McGeer

Tatsuo Yamada

Kaan E Biron

Shawna Rose Stanwood

Franz Fenninger

Dara L Dickstein

Lonna Munro

Cheryl Gurine Pfeifer

Qian-Jin Zhang

Michael R Food

Brett Alexander Eyford

Mei Mei Tian

Sylvia Rothenberger

Malcolm Kennard

Judie Barbara Alimonti

Gerassimos Kolaitis

Genc Basha

Iryna Yuriyivna Saranchova

Gregor S D Reid

Quian-Jin Zhang

Gregor S Reid

Judi Barbara Alimonti

Muriel D David

Timothy Vitalis

Alverina F Setiadi

Robyn P Seipp

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

Antibodies to L-type voltage gated channels and related methods

Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Curcuphenol compounds for increasing MHC-I expression

Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.

Methods for diagnosing and treating Alzheimer's disease

The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (IL-C2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.

Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44

Provided are conjugates between p97 (melanotransferrin) and polynucleotides such as small interfering RNA (siRNA) molecules, and related compositions and methods of use thereof, for instance, to facilitate delivery of polynucleotides such as siRNA molecules across the blood-brain barrier (BBB) and/or improve their tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose various diseases, including those having a central nervous system (CNS) component.

P97-polynucleotide conjugates

The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.

P97 fragments with transfer activity

The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.

P97-antibody conjugates and methods of use

A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful in treating infectious diseases and cancer.

Method of enhancing an immune response

A vaccine composition for combatingviral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.

[object Object]

Growing community of inventors

Surrey, Canada

Wilfred A Jefferies